Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

HjalmarTheGreat Jul. 17 at 3:25 PM

$BCAB Low grade adverse effects. All (8/8) metastatic and unresectable melanoma pts safely achieved tumor reduction with evalstotug + anti-PD-1, including patients with only 1 scan, which will be further updated. It was notable that intrapatient evalstotug dose escalation safely re-attained tumor control, suggesting increasing evalstotug exposure can drive improved antitumor activity, even after months on anti-CTLA4 therapy. https://www.researchgate.net/publication/389268223_Abstract_A107_Updated_results_from_a_study_of_evalstotug_BA3071_an_anti-CTLA-4_conditionally_active_biologic_in_melanoma

0 · Reply

HjalmarTheGreat Jul. 17 at 3:20 PM

$BCAB https://www.researchgate.net/publication/390982867_Abstract_2693_BA3361_a_tumor_selective_conditionally_active_biologic_CAB_anti-nectin4-ADC_with_a_novel_NextGen_linker_system_enhances_therapeutic_efficacy_in_pancreatic_cancer?_sg=r_XULHolKQl8ZVLhPCTLve9YjhboQz_YtwZWUdbcwozYLeBYQeD8iuCmFm_psUdAJgvYrS48KfHw7Ww&_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InByb2ZpbGUiLCJwYWdlIjoiX2RpcmVjdCJ9fQ "Complete tumor regression in several patient derived cancer models."

1 · Reply

DARKP00L Jul. 17 at 12:54 PM

$BCAB 08:52 on Jul. 17 2025 BioAtla To Present First-In-Human Phase I Study Of Dual- CAB EpCAM x CD3 Bispecific T-Cell Engager, BA3182, In Patients With Treatment Refractory Metastatic Adenocarcinoma, At ESMO TAT Asia Meeting #tradeideas

0 · Reply

King_of_Bio Jul. 17 at 12:33 PM

$BCAB Investing in new bios always comes with risk - hopefully they can pull it off here. Good luck bulls

0 · Reply

HjalmarTheGreat Jul. 17 at 1:16 AM

$BCAB “Confident in a non-dilutive partnership.” I believe it's coming. I'll keep buying no matter how hard it gets.

0 · Reply

HjalmarTheGreat Jul. 15 at 5:13 PM

$BCAB Bristol Myers Squibb is still collaborating with Bioatla. I predict a a few scenarios regarding the situation Bioatla is in. 1: BMS will acquire Bioatla at a discounted rate. 2: BCAB and BMS will champion/renegotiate the terms of their collaboration. This collaboration is too far along for BMS to allow it to fail, particularly if the results so far are promising. 3: The results aren't that promising. BMS walks and I lose a fortune along with the other 7 guys who are accumulating this. :(

1 · Reply

HjalmarTheGreat Jul. 15 at 2:52 PM

$BCAB Insiders loaded the boat on this one in June. Time will tell if I'm right on this one, or the worst trader ever.

1 · Reply

BiotechValues Jul. 14 at 7:19 PM

$BCAB Million dollar question. What was the plan they submitted to the Nasdaq? Clearly Nasdaq accepted it. Only a couple ways to increase shareholder's equity - one of which is a deal

2 · Reply

asdfadfsadsafdfassdf Jul. 14 at 4:47 PM

$BCAB

0 · Reply

HjalmarTheGreat Jul. 14 at 3:11 PM

$BCAB Alright alright alright.

0 · Reply

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$

Jul 3, 2025, 8:00 AM EDT - 14 days ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jun 2, 2025, 8:00 AM EDT - 6 weeks ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

May 6, 2025, 5:55 PM EDT - 2 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 2 months ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Apr 30, 2025, 8:00 AM EDT - 2 months ago

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 2 months ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 24, 2025, 8:00 AM EDT - 3 months ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 3 months ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 6:18 PM EDT - 4 months ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 5:05 PM EDT - 4 months ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 4:05 PM EDT - 4 months ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 20, 2025, 8:00 AM EDT - 4 months ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 19, 2025, 8:00 AM EDT - 4 months ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 4, 2025, 7:34 AM EST - 4 months ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dec 20, 2024, 9:00 AM EST - 7 months ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 7 months ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 7 months ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Nov 9, 2024, 8:53 AM EST - 8 months ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Oct 8, 2024, 6:12 AM EDT - 10 months ago

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 7, 2024, 11:29 AM EDT - 10 months ago

BioAtla: Numerous Catalysts Coming In Q4

Oct 4, 2024, 9:05 AM EDT - 10 months ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 10 months ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 10 months ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 5:39 PM EDT - 1 year ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

May 29, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 8, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 2, 2024, 10:03 AM EDT - 1 year ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

Apr 24, 2024, 4:35 PM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 26, 2024, 7:21 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 4:01 PM EDT - 1 year ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Mar 19, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Mar 7, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Dec 20, 2023, 8:00 AM EST - 1 year ago

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 8:00 AM EST - 1 year ago

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Dec 6, 2023, 8:00 AM EST - 1 year ago

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

Dec 5, 2023, 8:00 AM EST - 1 year ago

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Nov 30, 2023, 8:00 AM EST - 1 year ago

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

Nov 28, 2023, 8:00 AM EST - 1 year ago

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

Nov 12, 2023, 5:38 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:01 PM EST - 1 year ago

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Nov 6, 2023, 4:05 PM EST - 1 year ago

BioAtla to Participate in the Jefferies London Healthcare Conference

Oct 12, 2023, 7:30 AM EDT - 1 year ago

BioAtla's Jay M. Short, Ph.D.

Oct 10, 2023, 7:30 AM EDT - 1 year ago

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

HjalmarTheGreat Jul. 17 at 3:25 PM

0 · Reply

HjalmarTheGreat Jul. 17 at 3:20 PM

1 · Reply

DARKP00L Jul. 17 at 12:54 PM

0 · Reply

King_of_Bio Jul. 17 at 12:33 PM

$BCAB Investing in new bios always comes with risk - hopefully they can pull it off here. Good luck bulls

0 · Reply

HjalmarTheGreat Jul. 17 at 1:16 AM

$BCAB “Confident in a non-dilutive partnership.” I believe it's coming. I'll keep buying no matter how hard it gets.

0 · Reply

HjalmarTheGreat Jul. 15 at 5:13 PM

1 · Reply

HjalmarTheGreat Jul. 15 at 2:52 PM

$BCAB Insiders loaded the boat on this one in June. Time will tell if I'm right on this one, or the worst trader ever.

1 · Reply

BiotechValues Jul. 14 at 7:19 PM

$BCAB Million dollar question. What was the plan they submitted to the Nasdaq? Clearly Nasdaq accepted it. Only a couple ways to increase shareholder's equity - one of which is a deal

2 · Reply

asdfadfsadsafdfassdf Jul. 14 at 4:47 PM

$BCAB

0 · Reply

HjalmarTheGreat Jul. 14 at 3:11 PM

$BCAB Alright alright alright.

0 · Reply

LabPsycho Jul. 14 at 1:24 PM

$BCAB IMO, I guess if it gets bad enough BCAB could just do one of these reverse merger cryto scams like SONN just did and become a transformative cryptotreasury company. .

0 · Reply

updownsides Jul. 14 at 2:36 AM

$BCAB BioAtla is developing BA3182 as a potential anticancer therapy for patients with advanced adenocarcinoma, which is the largest group of cancers. BA3182 has the potential to serve *over one million patients* globally and could be a best-in-class bispecific TCE for multiple solid tumor types. Preclinical studies using dual CAB BA3182 demonstrated potent antitumor activity in a human colorectal carcinoma xenograft model with a greater than *a 100-fold* improvement in the therapeutic index compared to non-CAB EpCAM x CD3 variants. Updated Phase 1 data are anticipated --->2H2025.<--- https://bioatla.gcs-web.com/news-releases/news-release-details/bioatla-presents-data-ongoing-dose-escalation-ba3182-dual

0 · Reply

HjalmarTheGreat Jul. 11 at 7:19 PM

$BCAB I find it interesting that Bioatla is filing patents along with Exuma Biotech. More is going on here than people realize.

2 · Reply

HjalmarTheGreat Jul. 11 at 6:32 PM

$BCAB https://finance.yahoo.com/news/bioatla-jay-m-short-ph-113000350.html The CAB portfolio has been on the radar for a while now. Jay Short won the Lowell Thomas Award for his CAB research less than two years ago. Someday this will be a sneaky runner and I'll be here for it.

0 · Reply

UncleGs Jul. 10 at 7:39 PM

$BCAB

0 · Reply

jayhwan Jul. 10 at 3:40 PM

$BCAB Epcam에 SC 제형인데 이걸 안 사? 얼른 쌈@뽕하게 가보자 틀라야

0 · Reply

Tom678 Jul. 10 at 2:32 PM

$BCAB $IGC same thing happened yesterday , towards the closing bell it skyrocketed

1 · Reply

Jghamz94 Jul. 10 at 2:27 PM

$IGC hopefully we see another spike here soon, volume seems to be picking back up a bit. Keep $BCAB on your radars, get in early before the run 📈

0 · Reply

Tom678 Jul. 10 at 1:17 PM

$BCAB $IGC exactly

0 · Reply

asdfadfsadsafdfassdf Jul. 10 at 1:17 PM

$BCAB $IGC the results coming back from the trials are phenomenal. Not a single insider has dumped shares. No BS gluff press releases to try to artificially juice the SP. I think there is a huge amount of potential.

0 · Reply

HjalmarTheGreat Jul. 10 at 2:58 AM

$BCAB $IGC ran (which i also hold.) if we cant pull another big run out here…. not big…. epic…. it will speak volumes about whats wrong with the world. The science at $IGC isn’t unique nor special, others do the same thing. $BCAB? good. good science. sharing my wisdom because:

0 · Reply

bolttrades Jul. 9 at 8:13 PM

$BCAB do a deep dive on jay m short if you haven’t

0 · Reply

Market Cap	23.01M
Revenue (ttm)	11.00M
Net Income (ttm)	-69.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-634.36%
Debt to Equity Ratio	0.00

Volume	1,086,100
Avg Vol	537,646
Day's Range	N/A - N/A
Shares Out	58.42M
Stochastic %K	42%
Beta	0.91
Analysts	Strong Sell
Price Target	$8.33